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Introduction. More information is needed about the safety of low-dose primaquine in populations where G6PD deficiency is 
common.
Methods. Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 artemisinin combination therapies 
(ACTs) with or without primaquine (0.25 mg/kg). Glucose-6-phosphate dehydrogenase (G6PD) status was determined using a rapid 
test. Patients were followed for 28 days to record hemoglobin concentration, adverse events, and gametocyte carriage. The primary 
end point was the change in Hb at day 7.
Results. In sum, 274 patients were randomized, 139 received an ACT alone, and 135 received an ACT + primaquine. The mean 
reduction in Hb at day 7 was similar in each group, a difference in the ACT + PQ versus the ACT alone group of −0.04 g/dL (95% 
confidence interval [CI] −0.23, 0.31), but the effect of primaquine differed according to G6PD status. In G6PD-deficient patients the 
drop in Hb was 0.63 g/dL (95% CI 0.03, 1.24) greater in those who received primaquine than in those who received an ACT alone. In 
G6PD-normal patients, the reduction in Hb was 0.22 g/dL (95% CI −0.08, 0.52) less in those who received primaquine (interaction 
P = .01). One G6PD normal patient who received primaquine developed moderately severe anaemia (Hb < 8 g/dL). Dark urine was 
more frequent in patients who received primaquine. Primaquine was associated with a 73% (95% CI 24–90) reduction in gametocyte 
carriage (P = .013).
Conclusion. Primaquine substantially reduced gametocyte carriage. However, the fall in Hb concentration at day 7 was greater 
in G6PD-deficient patients who received primaquine than in those who did not and one patient who received primaquine developed 
moderately severe anemia.
Clinical Trial registration. PACTR201411000937373 (www.pactr.org)
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Progress in the fight against malaria [1] has led many malar-
ia-endemic countries to outline a vision for malaria elimination 
[2, 3]. The World Health Organization (WHO) recommends 
the addition of a single low-dose of primaquine (0.25 mg/kg) 
to artemisinin combination therapy (ACT) for treatment of 
uncomplicated Plasmodium falciparum malaria as a component 
of pre-elimination or elimination programs [4]. Primaquine 
has been used for over 60 years in treating Plasmodium vivax 
and as a P. falciparum gametocytocide [5]. Primaquine rapidly 
kills mature gametocytes and could contribute to the reduction 
of malaria transmission [6]. However, countries in sub-Saharan 
Africa have been reluctant to use primaquine due to a lack of 
evidence about safety of the low-dose regimen in individuals 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency 
[6]. Primaquine at higher doses causes acute haemolytic anae-
mia in G6PD-deficient patients [7], but there is limited infor-
mation about the safety of the lower dose in populations where 
G6PD deficiency is common. In sub-Saharan Africa, G6PD 
deficiency is usually due to the G6PD (A-) allele [8]. The A- 
G6PD variant is associated with about 12% of normal enzy-
matic activity. Estimates of the frequency of this mutation in 
sub-Saharan Africa range from 5% to 25% [9, 10] but its fre-
quency has been underestimated [11]. The G6PD A- phenotype 
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is caused by the mutation A376G in the presence of 1 of 4 other 
mutations: G202A, G680T, T968C, or 542T, but some studies 
considered only the 376G/202A mutation. The 202 mutation is 
relatively uncommon in Senegal. In Niakhar, 12% of boys were 
G6PD deficient, and the 376G/968C genotype was the most 
prevalent [12]. In neighbouring Gambia, G6PD A- is also most 
commonly associated with the 968C mutation [13]. Although 
most individuals with the G6PD A- polymorphic variant are 
asymptomatic, acute hemolytic anemia can occur in heterozy-
gous females, as well as in homozygous females and hemizy-
gous males, under conditions of oxidative stress on red blood 
cells [10, 14]. This can be induced by infections and by drugs 
including the antimalarials primaquine and dapsone [15]. 
Hemolysis caused by primaquine is dose-related, and the risk 
is lower in patients given a single dose [16, 17] than in those 
given multiple doses over several days to eliminate P.vivax hyp-
nozoites [18].
In studies in Mali and Burkina Faso, administration of a 
single dose of primaquine (0.25 mg/kg or 0.4 mg/kg) reduced 
gametocyte carriage and infectiousness without clinically sig-
nificant haemolysis, but these studies did not include G6PD-
deficient participants [19, 20]. In Tanzania, Mwaiswelo et  al 
assessed the effect of low-dose primaquine in G6PD-deficient 
and normal malaria patients [21]. Three patients in each arm of 
the trial developed severe anemia, but none had a fall in hemo-
globin concentration of more than 25%. We are not aware of any 
other studies in Africa.
In Senegal, elimination of malaria is planned in the cen-
tral and northern parts of the country where incidence is 
low [22]. Introducing primaquine in these areas may help to 
reduce transmission, but evidence of safety is required before 
its use can be recommended. This study assessed the safety of 
adding a single fixed low-dose of primaquine (one tablet of 
15  mg, corresponding to 0.25  mg/kg for a person weighing 
60  kg) to the ACT regimens artemether-lumefantrine (AL), 
artesunate-amodiaquine (ASAQ), and dihydroartemisinine- 
piperaquine (DHA-PQ), when used to treat adult patients with 
P. falciparum malaria.
METHODS
Study Design and Population
An open-label randomized trial was undertaken in adult 
patients presenting with malaria at Deggo health post, Pikine, 
Dakar, Senegal. Patients >18  years with P.  falciparum malaria 
were enrolled if they had monospecific infection with parasite 
density 1000–100 000 trophozoites/μL and gave signed consent, 
and were randomized individually to receive AL, DHA-PQ, or 
ASAQ either alone or with primaquine. Patients were excluded 
if they were pregnant (confirmed by urine testing), breastfeed-
ing, had a history of hypersensitivity to any of the study drugs, 
had severe malaria, moderately severe anemia (hemoglobin 
<8 g/dL), or had a chronic illness.
Randomization, Treatment Allocation, and Follow-Up
Treatment assignments, prepared in permuted blocks of 18 
using Stata 12 (Statacorp, College Station, Texas), were placed 
in numbered, sealed, opaque envelopes, which were opened 
in sequence by the study pharmacist at the time of treatment. 
The pharmacist was not involved in patient screening or 
assessment of outcomes. The study was not blinded, but lab-
oratory technicians responsible for hemoglobin measurement 
and microscopy were unaware of treatment allocations. Fixed 
ACT combinations were used. For AL, tablets containing 20 mg 
artemether and 120  mg lumefantrine (Novartis) were given 
twice daily at the clinic; for DHA-PQ, patients received 3 tab-
lets (of 40  mg dihydroartemisinin plus 320  mg piperaquine, 
Holley-Cotec Pharmaceuticals Co., Ltd) per day for 3  days, 
whereas for ASAQ, 2 tablets of 100 mg artesunate plus 270 mg 
amodiaquine (Sanofi-Aventis) were given per day for 3  days. 
One tablet of primaquine (15  mg, Sanofi-Aventis) was given 
to patients who were randomized to the ACT  +  primaquine 
groups. Primaquine was given at day 0 in addition to the first 
dose of ACT under the direct observation of the research team. 
After each treatment dose, participants were observed for 
30 minutes and treatment readministered if the patient vomited. 
Patients who vomited a second time were withdrawn from the 
study and treated with quinine. Primaquine and AL were given 
with biscuits (to provide fat as recommended by the manufac-
turer). Clinical assessment was done on days 0, 1, and 2; subse-
quent visits were scheduled on days 3, 7, 14, 21, and 28. At each 
of these visits, hemoglobin concentration (Hb) was measured 
and adverse events were recorded. Adverse events, graded using 
a severity scale adapted from the WHO toxicity grading scale 
for determining the severity of adverse events, were classified as 
minor, moderate, or severe [23]. Urine samples were collected 
into clean containers at each visit and urine colour assessed by 
the study physician using Hillman’s chart. Grades 3–6 define an 
abnormally dark urine color (grade 3 and 4, moderate; grade 5 
and 6, very dark urine) [24].
Hb was measured using a HemoCue machine (HemoCue® 
Hb 301, Angelholm, Sweden). A qualitative test of G6PD activ-
ity (CareStartTM G6PD; Access Bio. Inc., New Jersey, USA; Lot 
GP15J02) was done on day 0 using a finger-prick blood sample. 
The CareStart G6PD deficiency Rapid Diagnostic Test (RDT) is 
a qualitative enzyme chromatographic test based on the reduc-
tion of colorless nitro blue tetrazolium dye to dark-colored for-
mazan. The sensitivity and specificity for this test range from 
90% to 98% and from 87% to 96%, respectively [25, 26]. Thick 
and thin blood films were taken at enrollment (day 0) and on 
days 1, 2, 3, 7, 14, 21, and 28. Further details of laboratory meth-
ods are given in the Supplement.
Statistical Methods
The primary endpoint was the change in Hb from day 0 to day 
7. A reduction in Hb of 0.3 g/dL or less due to primaquine was 
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considered to be small enough to be of no clinical concern. An 
interim analysis conducted to assess safety showed that the 
standard deviation of the change in Hb was 2.54 g/dL and on this 
basis a total sample size of 350 patients would be needed to have 
a 95% confidence interval that excluded a difference of 0.3 g/dL 
or more between groups. Secondary endpoints included change 
in Hb by day 3, day 14, day 21, and day 28; anemia (Hb < 11 g/dL) 
at any time up to day 28; clinical adverse events up to day 28, 
and the prevalence and density of gametocyte carriage during 
follow-up. The effect of primaquine on Hb was estimated using 
a mixed model, with time, treatment group, interaction between 
time and treatment, ACT regimen and gender as fixed effects, 
baseline Hb as a covariate, and patient as a random effect. The 
treatment difference at each time point, with a 95% confidence 
interval, was obtained from this model. A  planned subgroup 
analysis estimated the effect of primaquine in G6PD normal 
and G6PD deficient patients, by fitting a model that included 
G6PD status, the interaction between time and G6PD status, 
and the interaction between treatment group and G6PD status 
at each time point, as fixed effects, baseline Hb as a covariate, 
and patient as a random effect. Wald P-values were obtained for 
testing interaction between G6PD status and treatment group 
at each time point, and the effect of treatment in G6PD normal 
and deficient patients, with a 95% confidence interval, at each 
time point was obtained from the model. Logistic regression 
was used to compare the proportion of G6PD normal and defi-
cient patients who had a drop in Hb of 2 g/dL or more by day 
7. Data were double-entered into an Access database. Analyses 
were conducted using Stata (StataCorp, Texas).
Ethics
The protocol was approved by the Conseil National de 
Recherche en Santé in Senegal.
RESULTS
During 2 malaria transmission seasons, 402 individuals with 
a history of fever and a positive malaria RDT were screened. 
The most frequent reason for exclusion was Hb < 8 g/dL at the 
time of screening (72 patients). In sum, 274 patients were ran-
domized; 262 (96%) completed 28 days of follow-up (Figure 1). 
Recruitment was stopped at this point as the end of the trans-
mission season had been reached, and the confidence interval 
on the difference in Hb by day 7 was within the prespecified 
range. Baseline characteristics were similar in all treatment 
groups (Table 1 and Table S1). The mean dose of primaquine 
received by patients was 0.24 mg/kg, range 0.15–0.35 (Figure 2).
Impact of Primaquine Treatment on Hb
The mean Hb on day 7 was similar in patients who received 
ACT alone and those who received ACT  +  primaquine. The 
Figure 1. Trial profile. In sum, 128 patients were excluded. Reasons for noninclusion: 72: hemoglobin <8 g/dl; 7: intended to leave the study area; 15: did not confirm 
enrollment; 11: positive pregnancy test; 23: hyperparasitemia. Abbreviations: AL, artemether-lumefantrine; ASAQ, amodiaquine-artesunate; DHAPQ, dihydroartemisinin-pip-
eraquine; PQ, primaquine.
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difference (ACT + PQ−ACT alone) adjusted for baseline was 
−0.23 g/dL (95% CI −0.68, 0.21) for AL, −0.02 (−0.49, 0.45) for 
ASAQ and +0.54 (0.03, 1.06) for DHA-PQ. As the P-value for 
the interaction of ACT type with primaquine was not significant 
(0.0728, Table 2), for subsequent analyses the estimates of the 
effect of primaquine assumed that the effect was constant across 
ACT types. The pooled estimate of the difference in Hb on day 
7 (ACT + PQ−ACT alone) was +0.06 g/dL (95% CI −0.22, 0.33; 
P  =  .681). Similar results were obtained at other time points. 
The estimates of differences at each time point obtained from 
the mixed model, adjusted for effects of ACT type, sex, and 
baseline Hb, are shown in Table 3.
Effect of Primaquine Treatment in G6PD-Deficient and Normal Participants
Fifty-four patients (20%) were G6PD-deficient; in this sub-
group, the mean Hb on day 7 was 0.63  g/dL (95% CI 0.03, 
1.24) lower in those who received primaquine than in those 
who received ACT alone (Table 4). In G6PD-normal patients, 
there was a slight increase in Hb on day 7 of 0.22 g/dL (95% 
CI −0.08, 0.52) in those who received primaquine com-
pared with those who did not. A test of interaction between 
primaquine and G6PD status gave a P-value of .01. There 
was no evidence of interaction on other days (Table 4). The 
mean Hb in G6PD-deficient and normal patients is shown 
for each time point in Figure  3. Figure  4 shows the change 
in Hb by day 7 plotted for individual patients against their 
baseline value.
Among G6PD-normal patients, the proportion with a drop 
in Hb of 2 g/dL or more at day 7 was 29% in the ACT group 
versus 24% in the ACT plus primaquine group, a risk ratio 
(RR) of 0.85 (95% CI 0.69, 1.04) (Table S3). Among G6PD-
deficient patients, 26% had a drop in Hb of 2 g/dL or more 
after treatment with ACT by day 7 compared with 31% after 
treatment with ACT plus primaquine (RR  =  1.19, 95% CI 
0.80, 1.76).
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Figure 2. Distribution of the primaquine dose administered to study participants 
(in mg/kg).
Table 2. Mean Change in Hemoglobin Concentration From Day 0 to day 7
ACT ACT + PQ
Mean 
Difference*(95% CI) P-value
AL
 Day 0 13.1 13.4 … …
 Day 7 11.9 11.9 −0.23 (−0.68, 0.21) .306
ASAQ
 Day 0 13.9 13.4 … …
 Day 7 12.1 11.8 −0.02 (−0.49, 0.45) .931
DHAP
 Day 0 13.4 13.2 … …
 Day 7 11.7 12.2 0.54 (0.03, 1.06) .040
Total
 Day 0 13.5 13.4 … …
 Day 7 11.9 11.9 0.06 (−0.22, 0.33) .681
Abbreviations: ACT, artemisinin combination therapy; AL, artemether-lumefantrine; 
ASAQ, amodiaquine-artesunate; CI, confidence interval; DHAP, dihydroartemisinin; PQ, 
primaquine.
*Estimated from linear regression comparing day 7 concentration in each group, adjusted 
for Hemoglobin on day 0 as a covariate. P-values not adjusted for multiplicity of compari-
sons. A test of the interaction between ACT type and PQ gave P = .0728. A more detailed 
version of this table is provided in Table S2, Supplement.
Table 1. Baseline Characteristics of the Six Study Groups of Patients
AL AL + PQ ASAQ ASAQ + PQ DHAPQ DHAPQ + PQ
No. Enrolled 51 51 49 47 39 37
Male:Female 37:14 38:13 36:11 36:11 31:8 26:11
Age in years (range) 28.7 (18–74) 32.6 (18–68) 29.0 (18–74) 30.0 (18– 63) 27.1 (18– 58) 29.9 (18– 57)
Weight in kg (range) 63.7 (45–86) 67.0 (45–97) 66.7 (46–111) 65.1 (50–108) 64.9 (43–90) 63.9 (44–102)
Height in cm (range) 176.1 (166–188) 174.7 (160–195) 175.1 (156–190) 173.0 (156–188) 174.6 (154–189) 177.4 (161–188)
BMI 20.6 (12.7–27.7) 22.0 (16.2–33.6) 21.9 (14.5–44.4) 21.8 (16.4–34.1) 21.0 (8.7–31.9) 20.3 (13.7–29.2)
BMI < 18 24% 7.8% 18% 17% 21% 24%
G6PD deficient 16% 20% 20% 30% 15% 16%
Geometric mean parasite 
density/μL (range)
11 805 (1240–63 590) 12 347 (1000–77 612) 13 933 (1003–91 421) 12 088 (1029–61 520) 13 848 (1163–78 130) 14 938 (1200–65 718)
Hb concentration g/dL 13.1 (8.9–18.4) 13.4 (8.9–18.0) 13.9 (9.6–17.7) 13.4 (8.7–18.2) 13.4 (9.2–18.2) 13.2 (8.8–16.7)
Anemia (Hb < 11 g/dL) 12% 10% 6.1% 13% 18% 11%
Abbreviations: AL, artemether-lumefantrine; ASAQ, amodiaquine-artesunate; BMI, body mass index; DHAPQ, dihydroartemisinin-piperaquine; PQ, primaquine.
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Anemia After Treatment With Primaquine
The proportion of patients with moderate anaemia (Hb < 11 g/dL) 
during the 28 day follow-up period was similar in those who 
received primaquine and those who received ACT alone, 
and there was no evidence of an interaction with G6PD sta-
tus (Table S4). One patient presented with moderately severe 
anemia (Hb < 8 g/dL), a man in the AL + primaquine group, 
whose baseline Hb was 12  g/dL and who was G6PD-normal. 
He received AL and one tablet of primaquine (0.22 mg/kg). His 
Hb was 8.4 g/dL on day 3 and 7.3 g/dL on day 7 (a 39% reduc-
tion from baseline) but with no clinical features of anemia. 
After supplementation with iron and folate, his Hb recovered 
to 11.2 g/dL by day 28.
Other Adverse Events
The incidence of adverse events was similar in all treatment 
groups (Table S5) except for the occurrence of dark-coloured 
urine, which was more common in patients who received 
primaquine and occurred during the first 3 days after the start 
of treatment; 79/135 (59%) of patients who received primaquine 
had dark urine (grade 3 or above) on day 1 after treatment ver-
sus 46/139 (33%) in those who received ACT alone (RR = 1.8, 
95% CI 1.3, 2.3; P < .001). The estimates on day 2 were 25% and 
12% (RR = 2.1, 95% CI 1.2–3.6; P = .007), and 4.5% and 1.5% 
(RR = 3.0, 95% CI 0.62–15; P = .148) on day 3. Those who had 
dark urine (grade 3 or above) on day 3 had a lower Hb on day 3 
than those who did not (1.42 g/dL, 95% CI 1.3, 1.6; P = .0393).
Parasitological Findings
The prevalence and density of gametocyte carriage were sub-
stantially lower in patients who received primaquine than in 
those who did not (Figure 5). The average duration of gameto-
cyte carriage was 1.08 days in those who received ACT alone 
compared to 0.29  days in the ACT  +  primaquine group, a 
reduction of 73% (95% CI 24%, 90%; P  =  .013). The area-
under-the-curve of gametocyte density over time was 106.7 
Table 3. Mean Hemoglobin Concentration at Each Time Point in Each Treatment Group, the Mean Change From Baseline, and the Difference Between 
Groups in the Change From Baseline Estimated From the Mixed Model
Day
Mean Hemoglobin Concentration (SD) Change From Baseline, Mean (SD)
Adjusted Difference between Groups in 
Change From Baseline (95% CI)
ACT ACT + PQ ACT ACT + PQ (ACT + PQ) − (ACT) P-Value
0 13.5 (1.82) 13.4 (1.94) … … … …
3 12.0 (1.65) 12.0 (1.76) −1.49 (1.35) −1.33 (1.32) 0.10 (−0.17, 0.37) .474
7 11.9 (1.43) 11.9 (1.65) −1.54 (1.35) −1.46 (1.47) 0.04 (−0.23, 0.31) .764
14 12.3 (1.49) 12.3 (1.31) −1.12 (1.66) −1.06 (1.60) 0.00 (−0.27, 0.27) .996
21 12.8 (1.35) 12.7 (1.24) −0.70 (1.62) −0.61 (1.50) 0.03 (−0.24, 0.30) .809
28 13.0 (1.28) 13.1 (1.19) −0.49 (1.60) −0.30 (1.77) 0.14 (−0.13, 0.41) .314
Abbreviations: ACT, artemisinin combination therapy; CI, confidence interval; PQ, primaquine; SD, standard deviation.
Table 4. The Mean Hemoglobin Concentration in G6PD Deficient and Normal Patients at Each Time Point, the Mean and Range of the Change From 
Baseline, and the Adjusted Effect of Primaquine on the Change From Baseline Estimated From the Mixed Effects Model
Day
G6PD
Mean Hb Concentration  
g/dL (SD)
Change From Baseline  
Mean (range)
Adjusted Difference in Change From 
Baseline (95% CI)
Status ACT ACT + PQ ACT ACT + PQ (ACT + PQ) − (ACT) P-Valuea
0 Normal 13.5 (1.86) 13.5 (1.95) … … … …
Deficient 13.3 (1.66) 13.0 (1.91)
3 Normal 12.0 (1.64) 12.2 (1.76) −1.47 (−6.4, +4.0) −1.31 (−4.0, +2.1) 0.15 (−0.15, 0.45) .544
Deficient 11.7 (1.71) 11.5 (1.70) −1.62 (−4.8, +0.6) −1.50 (−4.5, +1.3) 0.00 (−0.61, 0.61)
7 Normal 11.9 (1.37) 12.1 (1.66) −1.60 (−6.6, +1.4) −1.36 (−4.7, +3.3) 0.22 (−0.08, 0.52) .010
Deficient 12.1 (1.68) 11.2 (1.59) −1.24 (−3.6, +1.7) −1.75 (−6.1, +2.6) −0.63 (−1.24, −0.03)
14 Normal 12.4 (1.52) 12.5 (1.29) −1.09 (−5.9, +6.0) −1.00 (−4.8, +4.0) 0.07 (−0.23, 0.38) .344
Deficient 12.1 (1.35) 11.7 (1.21) −1.23 (−3.6, +2.7) −1.31 (−4.2, +2.1) −0.20 (−0.81, 0.41)
21 Normal 12.7 (1.36) 12.8 (1.31) −0.75 (−5.6, +3.6) −0.70 (−4.2, +3.8) 0.04 (−0.26, 0.34) .694
Deficient 12.9 (1.35) 12.6 (1.03) −0.45 (−3.3, +4.7) −0.36 (−2.9, +2.4) −0.04 (−0.65, 0.57)
28 Normal 13.0 (1.33) 13.2 (1.26) −0.51 (−5.0, +4.6) −0.32 (−3.7, +4.8) 0.18 (−0.13, 0.48) .625
Deficient 13.0 (1.05) 12.8 (0.87) −0.38 (−2.8, +3.9) −0.24 (−3.3, +3.0) 0.01 (−0.60, 0.62)
Abbreviations: ACT, artemisinin combination therapy; CI, confidence interval; PQ, primaquine; SD, standard deviation.
a The P-value is from a test of interaction between G6PD status and treatment.
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gametocyte-days in the ACT group and 29.5 gametocyte-days 
in the ACT + primaquine group, a reduction of 72% (95% CI 
16%, 91%; P = .024, Table 5).
DISCUSSION
In 2012, the WHO revised the previously recommended 
primaquine dose of 0.75  mg/kg to one of 0.25  mg/kg when 
used together with an ACT as a pre-elimination strategy [27]. 
However, primaquine is not often used in sub-Saharan African 
countries due to safety concerns, particularly in people with 
G6PD deficiency [18]. In our study, one patient, who received 
primaquine, developed moderately severe anemia (39% reduc-
tion from baseline). His hemoglobin recovered by day 28 with-
out any other adverse clinical findings. Overall, mean Hb on 
day 7 after treatment was similar in primaquine and ACT alone 
groups, but there was an interaction with G6PD status. In sum, 
20% of patients were G6PD deficient and in this group, mean 
Hb on day 7 was lower if they received primaquine by 0.63 g/dL, 
compared to G6PD deficient patients who received ACT alone. 
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Figure 4. Change in hemoglobin concentration by day 7 (Hb day 7-day 0) plotted against the concentration at baseline, for each group. Abbreviations: ACT, artemisinin 
combination therapy; PQ, primaquine.
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There was no evidence of a difference on day 3, or on and after 
day 14. Patients who received primaquine were more likely to 
have dark urine on days 1 to 3 after treatment, associated with 
a greater drop in Hb by day 3. This resolved by day 7. None of 
the patients with dark urine developed severe anemia or other 
clinically important symptoms. Primaquine is known to cause 
dark urine after multiple doses at higher doses [28], but we have 
shown that this symptom can also occur with the lower dose of 
0.25 mg/kg.
We are aware of only one other trial has investigated safety 
of low-dose primaquine in G6PD deficient patients in Africa 
[21]. In that study, in Tanzania, children and adults were 
enrolled, and, as in our study, patients whose baseline Hb was 
less than 8 g/dL were excluded; 15% of patients were phenotyp-
ically G6PD deficient. A slightly greater fall in Hb by day 7 was 
reported in patients who received primaquine and were G6PD 
deficient, but no test of interaction was performed. Analyses 
were also performed based on G6PD genotype, but typing was 
limited to the 376/202 mutation. No patients had clinically 
important reductions in Hb concentration. Hemoglobinuria 
was more frequent among G6PD-deficient patients treated with 
primaquine [21]. Repeated doses of 0.25 mg/kg primaquine in 
addition to DHA-PQ during mass drug administration cam-
paigns in healthy adults in Thailand did not induced clinically 
significant hemolysis in G6PD normal or deficient individuals 
[29].
In our study, addition of low-dose primaquine to ACT treat-
ment in adult patients resulted in a substantial reduction in 
gametocyte carriage. Reduced gametocyte carriage was also 
observed in studies in G6PD-normal patients in Mali and 
Burkina Faso [19, 20]. Thus, low-dose primaquine can sub-
stantially reduce infectiousness of malaria patients by killing 
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Figure 5. Gametocyte carriage over 28 days after treatment. A, Prevalence of gametocyte carriage. B, Arithmetic mean gametocyte density. Abbreviation: ACT, artemisinin 
combination therapy.
Table 5. Gametocyte Carriage at Baseline and After Treatmenta
Day
ACT (N = 139) ACT + PQ (N = 135)
No. Positive Prevalence
Gametocyte Density
No. Positive Prevalence
Gametocyte Density
Arithmetic Mean Geometric Mean Arithmetic Mean Geometric Mean
0 11 7.9% 32.9 347 9 6.7% 27.2 357
1 11 7.9% 27.1 260 8 5.9% 10.8 160
2 11 7.9% 12.9 107 8 5.9% 4.8 64
3 10 7.2% 7.0 59 4 3.0% 1.7 46
7 8 5.8% 4.1 51 2 1.5% 0.5 32
14 7 5.0% 2.4 39 0 0.0% 0.0 …
21 4 2.9% 1.2 18 0 0.0% 0.0 …
28 1 0.7% 0.2 24 0 0.0% 0.0 …
Area under the curve 1.08 106.7 0.29 29.5
Abbreviations: ACT, artemisinin combination therapy; PQ, primaquine.
aThe mean duration of gametocyte carriage was estimated as the area under the curve of gametocyte prevalence over time, i.e., ∑dij/ni where ni is the number of patients in group i and 
dij = ∑wtxtij, where xtij is the gametocyte status (0 or 1) at time t in patient j in group i, and the weightings wt are 0.25, 1, 1, 2.5, 5.5, 7, 10.5, and 7 for follow-up time points at 0, 1, 2, 3, 7, 14, 
21, and 28 days. This is equivalent to plotting for each patient the gametocyte status (0 or 1) against time, connecting the points with straight lines, calculating the area under the resulting 
line, and then taking the mean area in each treatment group. The percentage efficacy against gametocyte carriage was calculated as 100×(1-R) where R is the ratio of the mean duration in 
the two treatment groups estimated using Poisson regression of dij on treatment group, using a robust standard error to calculate confidence intervals and P-values. A similar analysis was 
done, replacing the value of xtij with the gametocyte density in patient j in group i at time t, in order to estimate the effect of treatment on gametocyte density during the 28-day follow-up.
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P. falciparum gametocytes with a high degree of efficacy, and it 
can do this in a single dose [19, 20, 30, 31].
In our trial, patients with Hb  <  8  g/dL were not enrolled. 
Under routine conditions, and especially during mass drug 
treatment studies, it may not be feasible to assess Hb prior to 
treatment for all individuals, and it would be difficult to pre-
dict how safe the drug would be in patients with lower Hb. In 
this trial, direct measurement of hemolysis was not possible. 
Measuring bilirubin, haptoglobin, methemoglobin, and reticu-
locyte count would be useful to determine whether the hemo-
globin reduction is due to hemolysis or other factors.
Primaquine has become a key tool for malaria elimination 
[32]. This study provides additional evidence that the cur-
rently recommended single dose of primaquine (0.25 mg/kg) 
is well tolerated. However, the way in which primaquine 
should be delivered in elimination settings is still under 
debate. Strategies under consideration for primaquine use 
include adding primaquine to the treatment of symptomatic 
cases; identifying and treating all malaria cases in mass screen 
and treat (MSaT) programs; or using primaquine as a com-
ponent of mass drug administration (MDA) programs [33]. 
Treating only symptomatic cases seen at health facilities may 
not have a substantial effect on transmission as these cases 
may represent only a small fraction of the infectious reservoir 
[34, 35]. MSaT and MDA have the potential substantially to 
reduce malaria transmission [36]. However, these strategies 
require drugs to be given to people who are not apparently 
ill and may not have malaria infection [37]. Further studies 
are therefore needed in order to determine the tolerability 
and acceptability of low-dose primaquine in MDA programs, 
and in patients with Hb lower than 8 g/dL. High coverage and 
adherence, essential for MDA programs to be effective, rely 
on good acceptability and tolerability of the drugs used [37]. 
The safety of primaquine among vulnerable groups such as 
pregnant woman and young children has not been well stud-
ied, but excluding these groups would limit the effectiveness 
of mass drug campaigns. Additional safety data on vulnerable 
groups may be needed to support the use of primaquine in 
elimination programs in Africa.
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